Trials / Active Not Recruiting
Active Not RecruitingNCT05022927
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
A PHASE I STUDY OF ERY974 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 179 (estimated)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, dose-escalation study designed to determine the maximum tolerated dose (MTD) by evaluating dose-limiting toxicities (DLTs) and to evaluate the safety, tolerability, pharmacokinetics, anti-tumor effect, and biomarkers of ERY974 in combination with atezolizumab and bevacizumab following premedication with tocilizumab in patients with locally advanced or metastatic HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ERY974 | ERY974 vial |
| DRUG | Tocilicumab | Tocilizumab vial |
| DRUG | Atezolizumab | Atezolizumab vial |
| DRUG | Bevacizumab | Bevacizumab vial |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2021-08-26
- Last updated
- 2024-09-05
Locations
11 sites across 2 countries: Japan, Taiwan
Source: ClinicalTrials.gov record NCT05022927. Inclusion in this directory is not an endorsement.